Skip to main content
×
Home

Guidelines for the recognition and management of mixed depression

  • Stephen M. Stahl (a1) (a2) (a3), Debbi A. Morrissette (a3), Gianni Faedda (a4) (a5), Maurizio Fava (a6), Joseph F. Goldberg (a7), Paul E. Keck (a8), Yena Lee (a9) (a10), Gin Malhi (a11), Ciro Marangoni (a5), Susan L. McElroy (a8), Michael Ostacher (a12) (a13), Joshua D. Rosenblat (a9) (a10), Eva Solé (a14), Trisha Suppes (a12) (a13), Minoru Takeshima (a15), Michael E. Thase (a16), Eduard Vieta (a14), Allan Young (a17), Mark Zimmerman (a18) and Roger S. McIntyre (a9) (a10)...
Abstract

A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM–5 codified a new nosological entity, the “mixed features specifier,” referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e.g., mixed depression, depression with mixed features, or depressive mixed states [DMX]). Current treatment guidelines, regulatory approvals, as well the current evidentiary base provide insufficient decision support to practitioners who provide care to individuals presenting with an MDE with mixed features. In addition, all existing psychotropic agents evaluated in mixed patients have largely been confined to patient populations meeting the DSM–IV definition of “mixed states” wherein the co-occurrence of threshold-level mania and threshold-level MDE was required. Toward the aim of assisting clinicians providing care to adults with MDE and mixed features, we have assembled a panel of experts on mood disorders to develop these guidelines on the recognition and treatment of mixed depression, based on the few studies that have focused specifically on DMX as well as decades of cumulated clinical experience.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Guidelines for the recognition and management of mixed depression
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Guidelines for the recognition and management of mixed depression
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Guidelines for the recognition and management of mixed depression
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
*Address correspondence to: Stephen M. Stahl, Department of Psychiatry, University of California–San Diego, Neuroscience Education Institute, 1917 Palomar Oaks Way, Suite 200, Carlsbad, California 92008, USA. (Email: smstahl@neiglobal.com)
References
Hide All
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Benazzi F. Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states). Eur Psychiatry. 2008; 23(1): 4048; Epub ahead of print Aug 30, 2007.
3. Hu J, Mansur R, McIntyre RS. Mixed specifier for bipolar mania and depression: highlights of DSM–5 changes and implications for diagnosis and treatment in primary care. Prim Care Companion CNS Disord. 2014; 16(2): pii: PCC.13r01599. Epub ahead of print Apr 17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116292/. Accessed January 29, 2017.
4. Sato T, Bottlender R, Sievers M, Schröter A, Kleindienst N, Möller HJ. Evaluating the inter-episode stability of depressive mixed states. J Affect Disord. 2004; 81(2): 103113.
5. Vieta E, Valentí M. Mixed states in DSM–5: implications for clinical care, education, and research. J Affect Disord. 2013; 148(1): 2836; Epub ahead of print Apr 2. http://www.jad-journal.com/article/S0165-0327(13)00232-2/pdf. Accessed January 29, 2017.
6. Solé E, Garriga M, Valentí M, Vieta E. Mixed features in bipolar disorder. CNS Spectr. 2017: 17; Epub ahead of print.
7. Cerullo MA, Strakowski SM. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr. 2013; 18(4): 199208; Epub ahead of print Mar 18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688656/. Accessed January 29, 2017.
8. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015. 29(5): 459525; Epub ahead of print May 12. http://journals.sagepub.com/doi/pdf/10.1177/0269881115581093. Accessed January 29, 2017.
9. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011; 13(4): pii: PCC.10r01097. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219517/. Accessed January 29, 2017.
10. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012; 15(7): 10151026; Epub ahead of print Jan 5. https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145711001817. Accessed January 29, 2017.
11. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition. Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009; 23(4): 346388; Epub ahead of print Mar 27. http://journals.sagepub.com/doi/pdf/10.1177/0269881109102919. Accessed January 29, 2017.
12. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11(2): 81109.
13. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord. 2012; 14(Suppl. 2): 2236.
14. Musetti L, Del Grande C, Marazziti D, Dell’Osso L. Treatment of bipolar depression. CNS Spectr. 2013; 18(4): 177187; Epub ahead of print Feb 8.
15. Nivoli AM, Murru A, Goikolea JM, et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012; 140(2): 125141; Epub ahead of print Nov 17, 2011.
16. Woo YS, Lee JG, Jeong JH, et al. Korean Medication Algorithm Project for Bipolar Disorder, third revision. Neuropsychiatr Dis Treat. 2015; 11: 493506; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348143/. Accessed January 29, 2017.
17. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15(1): 144; Epub ahead of print Dec 12, 2012.
18. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11(3): 225255.
19. Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP–BD–2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2016: pii: pyw109. Epub ahead of print. https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyw109. Accessed January 29, 2017.
20. Grunze H, Azorin JM. Clinical decision making in the treatment of mixed states. World J Biol Psychiatry. 2014; 15(5): 355368; Epub ahead of print May 14.
21. Takeshima M, Oka T. DSM–5-defined “mixed features” and Benazzi’s mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression? Psychiatry Clin Neurosci. 2015; 69(2): 109116; Epub ahead of print Jul 14, 2014. http://onlinelibrary.wiley.com/doi/10.1111/pcn.12213/full. Accessed January 29, 2017.
22. Koukopoulos A, Sani G. DSM–5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand. 2014; 129(1): 416; Epub ahead of print Apr 19, 2013.
23. Malhi GS, Lampe L, Coulston CM, et al. Mixed state discrimination: a DSM problem that wont go away? J Affect Disord. 2014; 158: 810; Epub ahead of print Jan 28.
24. Benazzi F, Akiskal HS. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res. 2006; 141(1): 8188; Epub ahead of print Nov 28, 2005.
25. Faedda GL, Marangoni C, Reginaldi D. Depressive mixed states: a reappraisal of Koukopoulos’ criteria. J Affect Disord. 2015; 176: 1823; Epub ahead of print Feb 4.
26. Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP–BD. Am J Psychiatry. 2009; 166(2): 173181; Epub ahead of print Jan 2. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2008.08050746. Accessed January 29, 2017.
27. Olgiati P, Serretti A, Colombo C. Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depress Anxiety. 2006; 23(7): 389397.
28. Maj M. “Mixed” depression: drawbacks of DSM–5 (and other) polythetic diagnostic criteria. J Clin Psychiatry. 2015; 76(3): e381e382; http://www.psychiatrist.com/jcp/article/Pages/2015/v76n03/v76n0324.aspx. Accessed January 29, 2017.
29. Perugi G, Angst J, Azorin JM, et al. Mixed features in patients with a major depressive episode: the BRIDGE–II–MIX study. J Clin Psychiatry. 2015; 76(3): e351e358.
30. Sani G, Napoletano F, Vohringer PA, et al. Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom.. 2014; 83(4): 213221; Epub ahead of print Jun 19.
31. Sani G, Vohringer PA, Napoletano F, et al. Koukopoulos’ diagnostic criteria for mixed depression: a validation study. J Affect Disord. 2014; 164: 1418; Epub ahead of print Apr 12.
32. Goldberg JF. Mixed depression: a farewell to differential diagnosis? J Clin Psychiatry. 2015; 76(3): e378e380; http://www.psychiatrist.com/jcp/article/Pages/2015/v76n03/v76n0323.aspx. Accessed January 30, 2017.
33. Prieto ML, Youngstrom EA, Ozerdem A, et al. Different patterns of manic/hypomanic symptoms in depression: a pilot modification of the Hypomania Checklist–32 to assess mixed depression. J Affect Disord. 2015; 172: 355360.
34. Axelson D, Goldstein B, Goldstein T, et al. Diagnostic precursors to bipolar disorder in offspring of parents with bipolar disorder: a longitudinal study. Am J Psychiatry. 2015; 172(7): 638646; Epub ahead of print Mar 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489996/. Accessed January 30, 2017.
35. Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord. 2003; 73(1–2): 113122.
36. Brietzke E, Moreira CLRL, Duarte SVB, et al. Impact of comorbid migraine on the clinical course of bipolar disorder. Compr Psychiatry. 2012; 53(6): 809812; Epub ahead of print Nov 20, 2011.
37. Oedegaard KJ, Fasmer OB. Is migraine in unipolar depressed patients a bipolar spectrum trait? J Affect Disord. 2005; 84(2–3): 233242.
38. Ortiz A, Cervantes P, Zlotnik G, et al. Cross-prevalence of migraine and bipolar disorder. Bipolar Disord. 2010; 12(4): 397403.
39. Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010; 71(11): 15181525; Epub ahead of print Jun 15. http://www.psychiatrist.com/JCP/article/Pages/2010/v71n11/v71n1115.aspx. Accessed January 30, 2017.
40. Angst J, Cui L, Swendsen J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010; 167(10): 11941201; Epub ahead of print Aug 16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145248/pdf/nihms249007.pdf. Accessed January 30, 2017.
41. Dudek D, Siwek M, Zielinska D, Jaeschke R, Rybakowski J. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review. J Affect Disord. 2013; 144(1–2): 112115; Epub ahead of print Aug 5, 2012.
42. Sharma V, Khan M, Smith A. A closer look at treatment-resistant depression: is it due to a bipolar diathesis? J Affect Disord. 2005; 84(2–3): 251257.
43. Rihmer Z, Gonda X. Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: the role of underlying bipolarity. Depress Res Treat. 2011; 2011: 906462. Epub ahead of print Apr 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096313/pdf/DRT2011-906462.pdf. Accessed January 30, 2017.
44. Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with bipolar II major depressive episode? J Affect Disord. 2009; 115(1–2): 234240; Epub ahead of print Aug 9, 2008.
45. Post RM, Leverich GS, Altshuler LL, et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry. 2012; 73(7): 924930; Epub ahead of print Mar 20.
46. Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J Clin Psychiatry. 2008; 69(11): 17511757; Epub ahead of print Aug 12, 2008.
47. Galvao F, Sportiche S, Lambert J, et al. Clinical differences between unipolar and bipolar depression: interest of BDRS (Bipolar Depression Rating Scale). Compr Psychiatry. 2013; 54(6): 605610; Epub ahead of print Jan 31.
48. Williams JB, Terman M, Link MJ, Amira L, Rosenthal NE. Hypomania interview guide (including hyperthymia): retrospective assessment version (HIGH–R). Depress Anxiety. 1999; 9(2): 92100.
49. Benazzi F. Depressive mixed state: dimensional versus categorical definitions. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(1): 129134.
50. Hergueta T, Weiller E. Evaluating depressive symptoms in hypomanic and manic episodes using a structured diagnostic tool: validation of a new Mini International Neuropsychiatric Interview (M.I.N.I.) module for the DSM–5 “With Mixed Features” specifier. Int J Bipolar Disord. 2013; 1: 21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230688/. Accessed January 30, 2017.
51. Zimmerman M, Chelminski I, Young D, Dalrymple K, Martinez JH. A clinically useful self-report measure of the DSM–5 mixed features specifier of major depressive disorder. J Affect Disord. 2014; 168: 357362; Epub ahead of print Jul 22.
52. Altinbas K, Ozerdem A, Prieto ML, et al. A multinational study to pilot the modified Hypomania Checklist (mHCL) in the assessment of mixed depression. J Affect Disord. 2014; 152–154: 478482.
53. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000; 157(11): 18731875; http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.157.11.1873. Accessed January 30, 2017.
54. Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self-Rating Mania Scale. Biol Psychiatry. 1997; 42(10): 948955.
55. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant–suicide controversy. J Affect Disord. 2005; 85(3): 245258.
56. Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009; 11(6): 559595; http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5618.2009.00737.x/full. Accessed January 30, 2017.
57. Akiskal HS, Benazzi F. Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states? Psychopathology. 2005; 38(5): 273280.
58. Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE Study. Arch Gen Psychiatry. 2011; 68(8): 791798; http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1107421. Accessed January 30, 2017.
59. Balazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 2006; 91(2–3): 133138; Epub ahead of print Feb 3.
60. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post-hoc analysis. J Clin Psychiatry. 2009; 70(10): 14241431; http://www.psychiatrist.com/JCP/article/Pages/2009/v70n10/v70n1011.aspx. Accessed January 30, 2017.
61. Benazzi F. Bipolar disorder: focus on bipolar II disorder and mixed depression. Lancet. 2007; 369(9565): 935945.
62. Bjorklund L, Horsdal HT, Mors O, Ostergaard SD, Gasse C. Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study. Acta Neuropsychiatr. 2016; 28(2): 7584; Epub ahead of print Sep 11, 2015.
63. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004; 161(9): 15371547; https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0021171/. Accessed January 30, 2017.
64. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry . 2009; 166(2): 164172; Epub ahead of print Nov 17, 2008. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2008.08030322. Accessed January 30, 2017.
65. Möller HJ, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci. 2006; 256(1): 116; Epub ahead of print Aug 4, 2005.
66. Nierenberg AA. An analysis of the efficacy of treatments for bipolar depression. J Clin Psychiatry. 2008; 69(Suppl. 5): 48.
67. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170(11): 12491262; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091043/. Accessed January 30, 2017.
68. Pae CU, Vohringer PA, Holtzman NS, et al. Mixed depression: a study of its phenomenology and relation to treatment response. J Affect Disord. 2012; 136(3): 10591061; Epub ahead of print Dec 14, 2011.
69. Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015; 5(12): e008341. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679886/pdf/bmjopen-2015-008341.pdf. Accessed January 30, 2017.
70. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant–suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006; 94(1–3): 313; Epub ahead of print May 19.
71. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012; 262(Suppl 1.): 148.
72. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011; 72(2): 156167; Epub ahead of print Oct 5, 2010. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0031744/. Accessed January 30, 2017.
73. Tundo A, Calabrese JR, Proietti L, de Filippis R. Short-term antidepressant treatment of bipolar depression: are ISBD recommendations useful in clinical practice? J Affect Disord. 2015; 171: 155160; Epub ahead of print Sep 28, 2014.
74. Grunze H. The role of polypharmacy in bipolar disorder treatment guidelines. In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice Vol. II: Use of Polypharmacy in the “Real World.” New York: Springer Science; 2013: P. 275287.
75. Heijnen WT, De Fruyt J, Wierdsma AI, Sienaert P, Birkenhager TK. Efficacy of tranylcypromine in bipolar depression: a systematic review. J Clin Psychopharmacol. 2015; 35(6): 700705.
76. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate to severe mixed major depressive episodes: a post-hoc analysis. J Clin Psychiatry. 2015; 76(6): 728734; http://www.psychiatrist.com/jcp/article/Pages/2015/v76n06/v76n0607.aspx. Accessed January 30, 2017.
77. McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM–5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013; 150(2): 378383; Epub ahead of print May 25.
78. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015; 76(4): 398405; http://www.psychiatrist.com/jcp/article/Pages/2015/v76n04/v76n0402.aspx. Accessed January 30, 2017.
79. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400407; Epub ahead of print Nov 10, 2015.
80. Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014; 164: 5762; Epub ahead of print Jul 3.
81. Suppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 3743; Epub ahead of print Mar 19.
82. Patkar A, Gilmer W, Pae CU, et al. A 6-week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4): e34757. Epub ahead of print Apr 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335844/. Accessed January 30, 2017.
83. Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012; 32(4): 470478.
84. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2016: 19; Epub ahead of print.
85. Kelly T, Lieberman DZ. The utility of low-dose aripiprazole for the treatment of bipolar II and bipolar NOS depression. J Clin Psychopharmacol. 2017; 37(1): 99101.
86. Stahl SM. Prescriber’s Guide: Stahl’s Essential Psychopharmacology, 5th ed. New York: Cambridge University Press; 2014.
87. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997; 54(1): 3742.
88. Magiria S. Evidence-based combination therapy for bipolar disorder. In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice Vol. II: Use of Polypharmacy in the “Real World.” New York, NY: Springer Science; 2013: P. 159177.
89. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP–BD. Am J Psychiatry. 2007; 164(9): 13481355; http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2007.05122032. Accessed January 30, 2017.
90. Ei-Mallakh RS, Karippot A. Antidepressant-associated chronic irritable dysphoria (acid) in bipolar disorder: a case series. J Affect Disord. 2005; 84(2–3): 267272.
91. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry. 2009; 70(4): 450457; Epub ahead of print Apr 7.
92. Bauer M, Berman S, Stamm T, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Mol Psychiatry. 2016; 21(2): 229236; Epub ahead of print Jan 20, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790155/. Accessed January 30, 2017.
93. Stamm TJ, Lewitzka U, Sauer C, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75(2): 162168.
94. Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016; 77(4): e457e466.
95. Berk M, Dean O, Cotton SM, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 2011; 135(1–3): 389394; Epub ahead of print Jun 29.
96. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012; 73(1): 8186; Epub ahead of print Aug 9, 2011.
97. Geoffroy PA, Etain B, Franchi JA, Bellivier F, Ritter P. Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders. Curr Pharm Des. 2015; 21(23): 33523358.
98. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014; 29(3): 216223; Epub ahead of print Mar 16.
99. Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014; 75(9): 10101018.
100. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013; 74(11): 11011107; https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0061792/. Accessed January 30, 2017.
101. Taylor MJ, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Database Syst Rev. 2004; 2: CD004049.
102. Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014; 29(1): 5563; Epub ahead of print Dec 3, 2013.
103. Kraus C, Rabl U, Vanicek T, et al. Administration of ketamine for unipolar and bipolar depression. Int J Psychiatry Clin Pract. 2017: 112; Epub ahead of print.
104. McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015; 9: CD011611. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011611.pub2/abstract. Accessed January 30, 2017.
105. Dell’Osso B, Ketter TA. Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data. Int Clin Psychopharmacol. 2013; 28(6): 297304.
106. Muneer A. Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin Psychopharmacol Neurosci. 2015; 13(1): 2535; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423161/pdf/cpn-13-25.pdf. Accessed January 30, 2017.
107. Dilsaver SC, Benazzi F, Akiskal HS. Mixed states: the most common outpatient presentation of bipolar depressed adolescents? Psychopathology. 2005; 38(5): 268272; Epub ahead of print Sep 21.
108. Dilsaver SC, Benazzi F, Rihmer Z, Akiskal KK, Akiskal HS. Gender, suicidality and bipolar mixed states in adolescents. J Affect Disord. 2005; 87(1): 1116.
109. Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet. 2012; 379(9820): 10561067; Epub ahead of print Feb 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488279/pdf/nihms415614.pdf. Accessed January 30, 2017.
110. Singh MK, Ketter T, Chang KD. Distinguishing bipolar disorder from other psychiatric disorders in children. Curr Psychiatry Rep. 2014; 16(12): 516.
111. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016; 388(10047): 881890; Epub ahead of print Jun 8.
112. Cohen LS, Wang B, Nonacs R, Viguera AC, Lemon EL, Freeman MP. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am. 2010; 33(2): 273293.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1068
Total number of PDF views: 4975 *
Loading metrics...

Abstract views

Total abstract views: 5229 *
Loading metrics...

* Views captured on Cambridge Core between 28th February 2017 - 19th November 2017. This data will be updated every 24 hours.